Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- Morgan Stanley analyst Craig Hettenbach downgraded the rating for Hims & Hers Health, Inc. HIMS from Overweight to Equal-Weight and raised the price target from $42 to $60. Hims & Hers Health shares closed at $60.47 on Friday. See how other analysts view this stock.
- Deutsche Bank analyst James Shin downgraded the rating for Merck & Co., Inc. MRK from Buy to Hold and lowered the price target from $128 to $105. Merck shares closed at $83.01 on Friday. See how other analysts view this stock.
- Wolfe Research analyst Alex Zukin downgraded Datadog, Inc. DDOG from Outperform to Peer Perform. Datadog shares closed at $131.01 on Friday. See how other analysts view this stock.
- Barclays analyst Gena Wang downgraded the rating for Moderna Inc MRNA from Overweight to Equal-Weight and lowered the price target from $111 to $45. Moderna shares closed at $32.99 on Friday. See how other analysts view this stock.
- Ladenburg Thalmann analyst Paul Fremont downgraded Portland General Electric Co POR from Buy to Neutral. Portland Gen Electric shares closed at $41.64 on Friday. See how other analysts view this stock.
Considering buying MRNA stock? Here’s what analysts think:
Read This Next:
Market News and Data brought to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
